Bengaluru-based Peptris Technologies receives a $9 million investment from the Department of Science and Technology as part of the government’s VIGOR program to accelerate artificial intelligence–based drug discovery and development. The project aims to advance four experimental drugs to technology readiness levels, requiring preclinical development, validation and preparation for clinical trials.
China’s latest five-year plan for its pharmaceutical industry includes the development of at least 25% of all first-in-class drugs as one of ten objectives. From 2026 to 2030, government policy will support drugmakers’ pursuits of new targets, mechanisms and modalities, focusing on major infectious and chronic diseases plus rare and pediatric conditions. Other objectives include 50 domestic drugmakers having at least $1.5 billion in annual sales and five products being blockbusters globally.
